Kairos Pharma, LTD. financial data

Symbol
KAPA on NYSE
Location
2355 Westwood Blvd. #139, Los Angeles, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.8M shares
Common Stock, Shares, Outstanding 12.8M shares
Common Stock, Value, Issued 13K USD
Weighted Average Number of Shares Outstanding, Basic 10.9M shares +5.57%
Weighted Average Number of Shares Outstanding, Diluted 10.9M shares +5.57%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14K USD -57.6%
General and Administrative Expense 369K USD +45.3%
Operating Income (Loss) -383K USD -33.4%
Nonoperating Income (Expense) -664K USD -2556%
Net Income (Loss) Attributable to Parent -1.05M USD -236%
Earnings Per Share, Basic -0.1 USD/shares -233%
Earnings Per Share, Diluted -0.1 USD/shares -233%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 4.74M USD
Intangible Assets, Net (Excluding Goodwill) 262K USD
Assets 5M USD
Liabilities, Current 1.67M USD
Liabilities 1.67M USD
Retained Earnings (Accumulated Deficit) -7.84M USD
Stockholders' Equity Attributable to Parent 3.33M USD
Liabilities and Equity 5M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 100M shares
Common Stock, Shares, Issued 12.8M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.22M USD +3149%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 11.2M USD
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares